Joo Guan Yeo

Joo Guan Yeo

Auto-generated profile, based on publicly available information

Joo Guan Yeo

Translational Immunology Institute, SingHealth Duke-NUS Academic Medical Centre, Singapore, Singapore

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 June 2022 in Nature Neuroscience
Verified
Journal Article
Open access
PDF file
PKPavanish Kumar
Pavanish Kumar
ALAmanda Lim
Amanda Lim
SHSharifah Nur Hazirah
Sharifah Nur Hazirah
CCCamillus Jian Hui Chua
Camillus Jian Hui Chua
ANAdeline Ngoh
Adeline Ngoh
SASalvatore Albani
Salvatore Albani
Epileptogenic triggers are multifactorial and not well understood. Here we aimed to address the hypothesis that inappropriate pro-inflammatory mechanisms contribute to the pathogenesis of refractory epilepsy (non-responsiveness to antiepileptic drugs) in human patients. We used single-cell cellular indexing of transcriptomes and epitopes by sequencing (CITE-seq) to reveal the immunotranscriptome of surgically resected epileptic lesion tissues. Our approach uncovered a pro-inflammatory microenvironment, including extensive activation of microglia and infiltration of other pro-inflammatory immune cells. These findings were supported by ligand–receptor (LR) interactome analysis, which demonstrated potential mechanisms of infiltration and evidence of direct physical interactions between microglia and T cells. Together, these data provide insight into the immune microenvironment in epileptic tissue, which may aid the development of new therapeutics.

1 October 2019 in Annals of Translational Medicine
Verified
Journal Article
Closed access
PDF file
JWJudith Wong
Judith Wong
JLJing Yao Leong
Jing Yao Leong
JLJan Hau Lee
Jan Hau Lee
SASalvatore Albani
Salvatore Albani
JYJoo Guan Yeo
Joo Guan Yeo
Acute respiratory distress syndrome (ARDS) is a clinical syndrome associated with oxygenation failure resulting from a direct pulmonary or indirect systemic insult. It is a complex etiological phenomenon involving an array of immune cells acting in a delicate balance between pathogen clearance and immunopathology. There is emerging evidence of the involvement of different immune cell types in ARDS pathogenesis. This includes polarization of alveolar macrophages (AMs), neutrophil netosis, the pro-inflammatory response of T helper 17 subsets, and the anti-inflammatory and regenerative role of T regulatory cell subsets. Knowledge of these pathogenic mechanisms has led to translational opportunities, for example, research in the use of methylprednisolone, DNAse, aspirin, keratinocyte growth factor and in the development of stem cell therapy for ARDS. Discovering subgroups of patients with ARDS afflicted with homogenous pathologic mechanisms can provide prognostic and/or predictive insight that will enable precision medicine. Lastly, new high dimensional immunomic technologies are promising tools in evaluating the host immune response in ARDS and will be discussed in this review.

12 March 2019 in Arthritis & Rheumatology
Verified
Journal Article
Open access
PDF file
JWJudith Wienke
Judith Wienke
FEFelicitas Bellutti Enders
Felicitas Bellutti Enders
JLJohan Lim
Johan Lim
JMJorre S. Mertens
Jorre S. Mertens
LHLuuk L. van Den Hoogen
Luuk L. van Den Hoogen
FWF. Van Wijk
F. Van Wijk
Objective: Objective evaluation of disease activity is challenging in patients with juvenile dermatomyositis (DM) due to a lack of reliable biomarkers, but it is crucial to avoid both under‐ and overtreatment of patients. Recently, we identified 2 proteins, galectin‐9 and CXCL10, whose levels are highly correlated with the extent of juvenile DM disease activity. This study was undertaken to validate galectin‐9 and CXCL10 as biomarkers for disease activity in juvenile DM, and to assess their disease specificity and potency in predicting the occurrence of flares.Methods: Levels of galectin‐9 and CXCL10 were measured by multiplex immunoassay in serum samples from 125 unique patients with juvenile DM in 3 international cross‐sectional cohorts and a local longitudinal cohort. The disease specificity of both proteins was examined in 50 adult patients with DM or nonspecific myositis (NSM) and 61 patients with other systemic autoimmune diseases.Results: Both cross‐sectionally and longitudinally, galectin‐9 and CXCL10 outperformed the currently used laboratory marker, creatine kinase (CK), in distinguishing between juvenile DM patients with active disease and those in remission (area under the receiver operating characteristic curve [AUC] 0.86–0.90 for galectin‐9 and CXCL10; AUC 0.66–0.68 for CK). The sensitivity and specificity for active disease in juvenile DM was 0.84 and 0.92, respectively, for galectin‐9 and 0.87 and 1.00, respectively, for CXCL10. In 10 patients with juvenile DM who experienced a flare and were prospectively followed up, continuously elevated or rising biomarker levels suggested an imminent flare up to several months before the onset of symptoms, even in the absence of elevated CK levels. Galectin‐9 and CXCL10 distinguished between active disease and remission in adult patients with DM or NSM (P = 0.0126 for galectin‐9 and P < 0.0001 for CXCL10) and were suited for measurement in minimally invasive dried blood spots (healthy controls versus juvenile DM, P = 0.0040 for galectin‐9 and P < 0.0001 for CXCL10).Conclusion: In this study, galectin‐9 and CXCL10 were validated as sensitive and reliable biomarkers for disease activity in juvenile DM. Implementation of these biomarkers into clinical practice as tools to monitor disease activity and guide treatment might facilitate personalized treatment strategies.

1 May 2017 in Journal of Intensive Care Medicine
Verified
Journal Article
Closed access
JWJudith Wong
Judith Wong
MJMark Jit
Mark Jit
RSRehena Sultana
Rehena Sultana
YMYee Hui Mok
Yee Hui Mok
JYJoo Guan Yeo
Joo Guan Yeo
JLJan Hau Lee
Jan Hau Lee
Sparse and conflicting evidence exists regarding mortality risk from pediatric acute respiratory distress syndrome (ARDS). We aimed to determine the pooled mortality in pediatric ARDS and to describe its trend over time. MEDLINE, EMBASE, and Web of Science were searched from 1960 to August 2015. Keywords or medical subject headings (MESH) terms used included “respiratory distress syndrome, adult,” “acute lung injury,” “acute respiratory insufficiency,” “acute hypoxemic respiratory failure,” “pediatrics,” and “child.” Study inclusion criteria were (1) pediatric patients aged 0 days to 18 years, (2) sufficient baseline data described in the pediatric ARDS group, and (3) mortality data. Randomized controlled trials (RCTs) and prospective observational studies were eligible. Data on study characteristics, patient demographics, measures of oxygenation, and mortality were extracted using a standard data extraction form. Independent authors conducted the search, applied the selection criteria, and extracted the data. Methodological quality of studies was assessed. Meta-analysis using a random-effects model was performed to obtain pooled estimates of mortality. Meta-regression was performed to analyze variables contributing to change in mortality over time. Eight RCTs and 21 observational studies (n = 2274 patients) were included. Pooled mortality rate was 24% (95% confidence interval [CI]: 19-31). There was a decrease in mortality rates over 3 epochs (≤2000, 2001-2009, and ≥2010: 40% [95% CI: 24-59], 35% [95% CI: 21-51], and 18% [95% CI: 12-26], respectively, P < .001). Observational studies reported a higher mortality rate than RCTs (27% [95% CI: 24-29] versus 16% [95% CI: 12-20], P < .001). Earlier year of publication was an independent factor associated with mortality. Overall mortality rate in pediatric ARDS is approximately 24%. Studies conducted and published later were associated with better survival.

1 May 2011 in Molecular Immunology
Verified
Journal Article
Closed access
BTBoon King Teh
Boon King Teh
JYJoo Guan Yeo
Joo Guan Yeo
LCLai Min Chern
Lai Min Chern
JLJinhua Lu
Jinhua Lu

25 July 2014 in Frontiers in Pediatrics
Verified
Journal Article
Open access
PDF file
JWJudith Ju-Ming Wong
Judith Ju-Ming Wong
TLTsee Foong Loh
Tsee Foong Loh
DTDaniela Testoni
Daniela Testoni
JYJoo Guan Yeo
Joo Guan Yeo
YMYee Hui Mok
Yee Hui Mok
JLJan Hau Lee
Jan Hau Lee
Aims: Acute respiratory distress syndrome (ARDS) represents the most severe form of acute lung injury .The aim of our study is to describe the epidemiology of pediatric ARDS in Singapore and compare the outcomes of ARDS using the following respiratory indices: PaO2/FiO2 ratio (P/F ratio), SpO2/FiO2 ratio (S/F ratio), oxygenation index (OI) and oxygen saturation index (OSI). Methods: We examined medical records of patients admitted to the Children’s Intensive Care Unit (CICU) in KK Women’s and Children’s Hospital from 2009 to 2012. Those who fulfilled criteria for the American-European Consensus Conference (AECC) definition for ARDS were identified. Demographic, clinical and radiographic information were extracted and analyzed. Results: We identified 70 patients with ARDS. Median age (interquartile range) was 6.2 (1.4, 10.4) years. The most common risk factor was pneumonia [50(71%)]. Overall mortality was 44 (63%) patients. 32 (56%) patients had an underlying chronic comorbidity; 18 (46%) were hematology-oncology conditions. 56 (80%) patients had multiorgan dysfunction. Adjunct therapies used in our patients included inhaled nitric oxide [5 (7%)], prone position [22 (31%)], steroids [26 (37%)] and neuromuscular blockade [26 (37%)]. A high OI and low PF ratio after 24 hours of diagnosis of ARDS were associated with mortality. From day 3 onwards, all four respiratory indices appropriately differentiated survivors from non-survivors. Severity based on the S/F ratio and OSI demonstrated association with decreased ventilator free days and ICU free days. Conclusion: Risk factors for mortality included having an underlying comorbidity, multiorgan dysfunction, a low PF ratio and high OI at 24 hours of ARDS. Abnormal SpO2 based measurements were reliable markers of poor outcomes in pediatric ARDS.